Targeted Drug Delivery Using Polymeric Nanoparticles for the Treatment of Cancer: A Review

A project submitted

by

Diandra Elizabeth Penheiro

ID: 11346006

Session: Summer, 2011

to

The Department of Pharmacy

in partial fulfillment of the requirements for the degree of

Bachelor of Pharmacy (Hons.)

BRAC
UNIVERSITY

Inspiring Excellence

Dhaka, Bangladesh

May, 2017

Dedicated to my mother

CERTIFICATION STATEMENT

This is to certify that this project titled "Targeted Drug Delivery Using Polymeric Nanoparticles for the Treatment of Cancer" submitted for the partial fulfillment of the requirements for the Bachelor of Pharmacy from the Department of Pharmacy, BRAC University constitutes my own work under the supervision of Ms. Zara Sheikh, Senior Lecturer and Academic Coordinator, Department of Pharmacy, BRAC University and that appropriate credit is given where I have used the language, ideas or writings of another.

Signed,

_____

Diandra Elizabeth Penheiro

Countersigned by the Supervisor

_____

Zara Sheikh

ACKNOWLEDGEMENT

I am extremely grateful to Dr. Eva Rahman Kabir, Chairperson, Department of Pharmacy, BRAC University for giving me the opportunity to complete my undergraduate project thesis work. I am also thankful to Ms. Zara Sheikh, my project supervisor. Without her continuous support and supervision, I would not have been able to complete my project successfully.

I would also thank the Department of Pharmacy, BRAC University for providing an excellent environment to complete undergraduate project thesis.

Lastly, I would like to thank my mother for her unending support.

ABSTRACT

Advances in the field of polymeric nanoparticles is rapidly progressing and offers new opportunities for targeted treatment of cancer. The targeted delivery of nanoparticles can overcome the problems associated with the conventional cancer therapy such as lack of water solubility, nonspecific biodistribution and lack of selectivity resulting in non-specific toxicity towards normal cells and lower dose of drugs delivered to cancer cells leading to poor bioavailability and low therapeutic indices. Nanoparticles have shown great promise as drug-delivery vectors that are capable of preferentially targeting large doses of chemotherapeutic agents or therapeutic genes into malignant cells while leaving the healthy cells free. Nanoparticles that are used as drug delivery systems are submicron-sized particles (3-200nm) or colloidal systems of submicron size (<1μm) are constructed from a large variety of materials such as polymers (polymeric nanoparticles, micelles, dendrimers), lipids (liposomes) viruses (viral nanoparticles) as well as organo-metallic compounds. Various polymers are currently being explored to modify the properties of polymeric matrix which enables greater encapsulation efficiency and high therapeutic load with controlled release ability for the treatment of cancer. The present review explores the various types of polymeric nanoparticles and the different ways in which they have been utilized for the successful treatment of cancer. Passive targeting and ligand based targeting using nanoparticles have been discussed in details and the applications of different types of nanoparticles in the effective treatment of cancer has been exemplified.

TABLE OF CONTENTS

CHAPTER 3: TYPES OF POLYMER BASED NANOCARRIERS FOR TARGETED CANCER THERAPY

Chapter 4: CONCLUSION

LIST OF TABLES **Page no.**

LIST OF FIGURES   **Page No.**

LIST OF ACRONYMS

PLGA: Poly(Lactide-Co-Glycolide)

PTX: Paclitaxel

5-FU: 5-Fluorouracil

DOX: Doxorubicin

TMX: Tamoxifen

MPEG: Methoxy-Polyethylene Glycol

CMC: Carboxymethyl Cellulose

GCS: Glycosylated Chitosan

HA: Hyaluronic Acid

PEG: Polyethylene Glycol

EAT: Ehrlich Ascites Tumor

PBLG: Poly(Γ-Benzyl-L-Glutamate)

P(CL-Co-HCL): Poly(E-Caprolactone-Co-Γ-Hydroxyl-E-Caprolactone)

HAS: Human Serum Albumin

PLC: Poly(D,L-Lactide-Co-Caprolactone)

PDLLA: Poly(D,L-Lactide)

PAMAM: Polyamidoamine

PEO:Polyethylene Oxide

PCL: Polycaprolactone

VEGF : Vascular Endothelial Growth Factor

FGF: Fibroblast Growth Factor

EPR: Enhanced Permeability and Retention Effect

NCT: Neutron Capture Therapy

MRI: Magnetic Resonance Imaging

MMPS: Matrix Metallo-proteinases

HeLa: Henrietta Lacks cell

SELEX: Systematic Evolution of Ligands by Exponential enrichment

PSMA: prostate-specific membrane antigen

RCP: carrier protein of riboflavin

FMN: flavin mononucleotide

FLUSPIO: FMN- coated ultra-small super paramagnetic iron oxide nanoparticles

ASGPRs: asialoglycoprotein receptors

MCF-7: human breast adenocarcinoma

HT-29: colorectal adenocarcinoma

NCI-H460: non-small-cell lung carcinoma

SF-268: glioblastoma

PLN: polymer lipid hybrid nanoparticulate system

CEA: anti-carcinembryonic

SMANCS: styrene-maleic anhydride-neocarzinostatin

GCSF: granulocyte colony-stimulating factor

Chapter 1
INTRODUCTION

1. INTRODUCTION

1.1 Background

Cancer is the second most common cause of death in the world (Prabhu, Patravale, & Joshi, 2015). The most commonly diagnosed cancers throughout the globe are lung cancer (accounting for 12.7% of the total number of cases), breast cancer (10.9%) and colorectal cancer (9.7%) and the most common type of cancer leading to death are lung cancer (18.2% of the total), stomach cancer (9.7%) and liver cancer (9.2%) (Ferlay, Shin, Bray, & et.al, 2008).

The implementation of nano-medicines in the field of drug delivery has led to exciting advances in the treatment of cancer. The barriers associated with the conventional cancer treatment includes non-specificity that causes off-target toxicity, thus destroying healthy cells poor circulation times resulting in decreased efficacy and drug resistance leading to decreased intra-tumoral retention(Dean, Wang, & Hua, 2015).

In this context, polymeric nanoparticles offer numerous advantages including high drug loading, controlled release profile, improved stability and prolonged circulation times with greater cellular uptake (Pridgen, Alexis, & Farokhzad, 2014).

1.2 Rationale of the study

Nanoparticles have shown great promise as drug-delivery vectors that are capable of preferentially targeting large doses of chemotherapeutic agents or therapeutic genes into malignant cells while leaving the healthy cells free(Sinha, Kim, & Shin, 2008);(Gu, Karnik, & Wang, 2007). Nanoparticles that are used as drug delivery systems are submicro-sized particles (3-200nm) or colloidal systems of submicron size (<1μm) are constructed from a large variety of materials such as polymers (polymeric nanoparticles, micelles, dendrimers), lipids (liposomes) viruses (viral nanoparticles) as well as organo-metallic compounds(Leamon & Reddy, 2004). Polymer systems offer immense flexibility in customization and optimization of nanocarriers to efficiently deliver new therapeutics and provide an integral step in aiding their progression to clinical practice (Shroff & Vidyasagar, 2013).

Furthermore, advances in the development of polymeric nanoparticles has also opened up new dimensions for the treatment of cancers as they can simultaneously target multiple sites

on tumour cells and enables better specificity and selectivity, thus reducing the need for higher dose and harm to the patient(Vlerken & Amiji, 2006).

1.3 Aim and objectives of the study

The aim of the review is to explore the various types of polymeric nanoparticles and the different ways in which they have been utilized for the successful treatment of cancer.

The objectives of the review are:

1. Elaborate the two primary ways for the targeted delivery of anticancer drugs by the nanoparticles (passive targeting and ligand based targeting),
2. Discuss the different types of polymeric nanoparticles characterized by their unique physicochemical structures,
3. Exemplify the applications of these different types of nanoparticles in the effective treatment of cancer.

Chapter 2

TARGETED DELIVERY OF NANOPARTICLES

2. TARGETED DELIVERY OF NANOPARTICLES

There are primarily two ways for the delivery of an anticancer drug to the target site by the nanoparticles (Figure 2.1). (Prabhu, Patravale, & Joshi, 2015)

1. Passive targeting
2. Ligand based targeting

Figure 2.1: Approaches for Targeted Delivery of Nanoparticles.

2.1 Passive targeting

Certain patho-physiological conditions, for example leaky vasculature, pH, temperature, and surface charge around the tumour are used for passive targeting of nanoparticles (Prabhu, Patravale, & Joshi, 2015).

2.1.1 Enhanced permeation and retention (EPR) effect

The unique pathophysiologic characteristics of tumour vessels are exploited by nano-particulate systems for passive targeting when the tumour volume exceeds 2mm^3, nutrition intake, waste excretion, and oxygen delivery is impaired due to limited diffusion (Byrne, Betancourt, & Brannon-Peppas, 2008). New blood vessels are generated by these rapidly growing cancerous cells. This phenomenon is called angiogenesis (or neovascularization). Some features of angiogenesis are irregular tortuosity, basement membrane abnormalities and the deficiency of pericytes lining up the endothelial cells. Due to such impairments, gaps in the leaky vessels are formed which range from 100 nm to 2µm depending upon the tumour type (Maeda, 2001). Poor lymphatic drainage also occurs in these tumours since there is high interstitial pressure at the core of the tumour rather than at the periphery. Thus, leaky vasculature and poor lymphatic flow together results in enhanced permeation and retention (EPR) effect. As the sizes of nanoparticles are smaller than the fenestrated blood vessels, they preferentially localize in the cancerous cells and thus remain entrapped in the tumour because of their higher retention ability as compared to the normal tissues (Carmeliet & Jain, 2000); (Byrne, Betancourt, & Brannon-Peppas, 2008);(Maeda, 2001).

2.1.2 Tumor microenvironment

The microenvironment around the tumour cells which is different from the normal cells can be utilized for passive targeting. The rate of metabolism is high in rapidly dividing cancer cells. An acidic environment is formed since these cells use glycolysis to maintain the supply of nutrients and oxygen(Pelicano, Martin, Xu, & Huang, 2006). pH-sensitive nanoparticulate systems are developed in a way so that they remain stable at a physiologic pH of 7.4 but then degrade for the release of the active drug target tissues have in lower pH values (Yatvin, Kreutz, Horwitz, & Shinitzky, 1980). Hyperthermia is associated with many pathological conditions such as the human ovarian cancer. The design of a thermo-sensitive polymeric system consists of a polymer that exhibits a low critical solution temperature (LCST). Precipitation of the polymer occurs if the temperature in the tumour is above LCST with subsequent release of the drug. Using ultrasound or photothermal means, it is possible to induce localized hyperthermia in tumors (Brewer, Coleman, & Lowman, 2011);(Cheng, Su, Wu, & Yeh, 2010).

Certain enzymes are also released by matrix metallo proteinases (MMPs) cancer cells. These are associated in the survival and movement mechanisms of the cancer cells (Deryugina & Quigley, 2006).

2.1.3 Surface Charge

Surface charge is a critical factor for passive targeting of the tumour. Tumour cells have relatively high negative surface charge compared to normal cells. Therefore cationic nanoparticulate systems can be used that electrostatically bind to negatively charged phospholipid headgroups that are expressed on tumour endothelial cells (Ran, Downes, & Thorpe, 2002); (Krasnici, Werner, & Eichhorn, 2003). The nature of polymeric surface charge (anionic, cationic or neutral governs cellular internalization and subcellular localization of the nanoparticulate systems and thus is responsible for the cytotoxicity potential of polymeric nanoparticles. Cationic nanoparticles have proven to be successful in delivering small interfering RNA (siRNA) to silence target gene in cancer cells and have also improved anticancer activity of Paclitaxel (Boyer, Teo, & Phillips, 2013); (Beh, Seow, & Wang, 2009).

2.2 Ligand Based Targeting

In this type of targeting, ligands are conjugated at the periphery of the nanoparticulate system in order to bind with the proper receptors at the target tumor site. The targeting ligands can be classified as proteins (antibody and its fragments), peptides, nucleic acids (aptamers), or small molecules and others (vitamins and carbohydrates). These generally bind to the receptor that is over expressed by the tumour cells or vasculature (Danhier, Feron, & Preat, 2010);(Kirpotin, Drummond, & Shao, 2006)**.** These targeting ligands greatly influence cellular uptake of nanoparticles which in turn is enhanced by the process of endocytosis. Due to the long circulation of nanoparticles the nanoparticles are able to efficiently deliver the therapeutic agent to the tumor site by EPR phenomenon (Drummond, K, Park, Benz, & Kirpotin, 2000);(Lopes de Menezes, Pilarski, & Allen, 1998).

2.2.1 Antibody based targeting

Antibodies fall into the category of targeting ligands owing to their availability and their attributes as specific and *in vivo* targeting ligands without depending on tumour enhanced permeability and retention (EPR) (Friedman, Claypool, & Liu, 2013). The two epitope

binding sites present in a single molecule of antibody permits greater selectivity and binding affinity for the target of interest (Yu, Park, & Jon, 2012).

Various therapeutic antibodies have been developed and approved by the FDA such as Rituximab (Rituxan®) for non-Hodgkin's lymphoma treatment (James & Dubs, 1997), Trastuzumab (Herceptin®) for breast cancer treatment (Albanell & Baselga, 1999), Bevacizumab (Avastin®) designed to inhibit angiogenesis (Ferrara, 2005), and Cetuximab (Erbitux®) for advanced colorectal cancer treatment (Van Cutsem, Kohne, Hitre, Zaluski, Chang Chien, & Makhson, 2009). However, these antibodies are expensive to manufacture and variations may occur from, batch to batch. Potential immunogenic responses may also be induced by antibodies and therefore to mitigate this response, antibodies have been engineered to produce humanized, chimeric, or fragmented forms of antibodies (Yu, Park, & Jon, 2012).

One of the most common pharmaceutical carriers for targeted drug delivery is immune-liposomes (antibody-directed liposomes). They have the unique ability to encapsulate both hydrophilic and hydrophobic therapeutic agents and their preparation is relatively simple. *In vivo* lung cancer targeted immuno-liposomes was developed by Wu *et al* (Lu, Chang, Chen, & Wu, 2011).

However, there are certain challenges associated for the targeting of nanoparticles such as antigen binding (monoclonal antibodies/mAb should have high target specificity and the nanoparticles should not affect the desired specificity), conjugation (antibody-nanoparticle/Ab-NP linkage should be highly efficient and site specific) and circulation time (the mAb-NP conjugate linker must be stable when circulating in the body). Immunogenicity and purity are additional factors as well. The body is likely to recognize the antibodies as foreign particles and thus can nullify the action of the targeted nanoparticles. Therefore, many conjugation techniques can be utilized such as exploiting lysine side-chain amines and cysteine sulfhydryl groups that produce heterogeneous mixtures of targeted NPs, each with different molar ratios of antibody and nanoparticles (Ab:NP), with a safe pharmacokinetic profile (Friedman, Claypool, & Liu, 2013).

2.2.2 Peptide based targeting

Due to smaller size, low immunogenicity and ease of manufacture at relatively low costs, peptides are considered to be attractive targeting molecules (Wang, Gu, Zhang, Chan,

Radovich-Moreno, & Shaikh, 2008). There are various methods for identifying peptide based targeting ligands. Generally, peptides are obtained from the binding regions of the protein of interest. It is also possible to identify peptide based-targeting ligands by utilizing phage display techniques. In the phage display technique, a phage display screen is used for the bacteriophages to display a range of targeting peptide sequences in a phage display library (approximately 10^{11} sequences) and a binding assay is used to select the target peptides (McCarthy, Bhaumik, Karver, Sibel-Erdem, & Weissleder, 2010).

At present Cilengitide, which is a cyclic peptide that has a binding affinity for integrin is under phase II clinical trials for the treatment of non-small cell lung and pancreatic cancer (Beekman, Colevas, Cooney, Dipaola, Dunn, & Gross, 2006). Adnectins are a new class of therapeutic proteins based on the fibronectin and designed to bind with high affinity and specificity to relevant targets. An adnectin for human VEGF receptor 2, a 40 amino acid thermostable and protease-stable oligopeptide, is under phase I clinical trials for several oncology indications (Lipovsek, 2010). Even though peptides have certain disadvantages such as target affinity being low and easily susceptible to proteolytic cleavage, these conditions can be avoided by synthesis of the peptides with D-amino acids (Yu, Park, & Jon, 2012). Peptides have been recently used to design multifunctional nanoparticles for the purpose of targeted cancer imaging and therapy (Yu, Park, & Jon, 2012). A breast tumour targeted nano drug was designed to transfer siRNA to the human breast cancer which allowed the non-invasive monitoring of siRNA delivery concurrently (Kumar, Yigit, Dai, Moore, & Medarova, 2010).

2.2.3 Aptamer based targeting

Oligonucleic acids (RNA or DNA) which have unique three-dimensional structures and the potential to bind with many biochemical targets from small molecules to large proteins are known as aptamers(Friedman, Claypool, & Liu, 2013). Aptamers that are capable of binding to a target of interest are selected through Systematic Evolution of Ligands by Exponential enrichment (SELEX) (Tuerk & Gold, 1990). The method involves rounds of target binding, partitioning binding from non-binding sequences, and multiplication of the enriched binding sequences the bioactive forms of target proteins on the surface of the cell (Daniels, Chen, Hicke, Swiderek, & Gold, 2003). Aptamers which have a high affinity and specificity for a target can be selected from libraries of 10^{15} random oligonucleotides.

Aptamers have greater advantages in terms of nanoparticles targeting compared to antibodies. They can be synthesized with a specific functional moiety of carboxylate, amino, sulfhydryl or aldehyde at only one end of the nucleic acid that serves as an aptamer. This type of synthesis allows for conjugations which are site specific without the production of heterogeneous mixtures and with hardly any variations from batch to batch (Friedman, Claypool, & Liu, 2013). Aptamers exhibit non-immunogenic properties, are non-toxic and can be modified for stability in circulation (de Campos, Coopusamy, Morris, Mayosi, & Khati, 2009); (Pagratis, Bell, Chang, Jennings, Fitzwater, & Jellinek, 1997).The aptamers can be selected *in vitro* and *in vivo* and can be subjected to repeated and reversible denaturation. Since aptamers are not animal or immune-response dependent, they can be chosen against weak immunogenic targets and toxins (Jayasena, 1999). They have a much smaller size (150kDa) in contrast to antibodies and they can produce compact structures which enable them to bind clefts, binding sites and enzymatic active sites (Khati, 2010).

More than 200 aptamers have been isolated till present (Lee, Hesselberth, Meyers, & Ellington, 2004); (Lee, Stovall, & Ellington, 2006). Example of FDA approved aptamer is Pegaptanib ($VEGF_{165}$) in 2004 for the treatment of neovascular macular degeneration. Another aptamer which is a nucleolin targeted aptamer is under phase II clinical trial (Bates, Kahlon, Thomas, Trent, & Miller, 1999); (Bates, Laber, Miller, Thomas, & Trent, 2009); (Mongelard & Bouvet, 2010). However, due to the degradation of the nuclease, rapid blood clearance may occur which can be lethal to the patient. This problem can be overcome by modification of pyrimidine at 2'-fluorine position or chemical modification with PEG can be done to increase bioavailability and pharmacokinetic properties (Bouchard, Hutabarat, & Thompson, 2010).

2'-fluoro-pyridine-RNA aptamers which are produced against the extracellular domain of prostate-specific membrane antigen (PSMA) are considered to be the best aptamers for targeted delivery (Lupold, Hicke, Lin, & Coffey, 2002). Self-assembled polymeric nanoparticles of doxorubicin have been delivered by using these aptamers(Bagalkot, Farokhzad, Langer, & Jon, 2006); (Kolishetti, Dhar, Valencia, Lin, Karnik, & Lippard, 2010).

2.2.4 Small- molecule based targets

The small molecules with variable structures and properties are cheaper to produce and have proven to be a class of the more prevalent targeting ligands conjugated to nanoparticles. The

different types of small molecules used are folate, carbohydrates, riboflavin, EGFR, transferrin and lectins(Yu, Park, & Jon, 2012).

2.2.4.1 Folate

Folate, a water soluble vitamin B6, is one of the most widely studied molecules for drug delivery as they are inexpensive, non-toxic, non-immunogenic with high binding affinity, stability upon storage and during circulation and are easily conjugated to nanocarriers(Low & Kularatne, 2009). It is an essential vitamin in humans for cell division and embryonic development (McCarthy, Bhaumik, Karver, Sibel-Erdem, & Weissleder, 2010). The folate receptor has been considered as a potential tumour marker that binds vitamin folate and folate-drug conjugates with a high affinity and transfers these bound molecules into the cells through receptor-mediated endocytosis (Cho, Xu, Shuming, Chen, & Shin, 2008). Since folate receptors are overexpressed in cancers, folate allows for the targeted delivery of imaging and therapeutic agents to the tumor due to its high binding affinity for the folate receptors. Certain theranostic agents have been produced by the combination of folate with drug delivery vehicles or inorganic nanoparticles (Yu, Park, & Jon, 2012); (McCarthy, Bhaumik, Karver, Sibel-Erdem, & Weissleder, 2010). A new folate receptor-targeted nanoparticle formulation of Paclitaxel was formulated using heparin as a carrier (heparin-folate-Taxol (Paclitaxel), HFT) and was tested in animal models which showed more potent activity against the growth of tumour xenografts compared to binary heparin-Taxol or the free Paclitaxel drug (Cho & Kim, 2007).

2.2.4.2 Carbohydrates

Carbohydrates are another type of small molecule targeting ligands which can distinguish selectively the cell surface receptors such as lectin(Zhang, Ma, & Sun, 2010). Hepatocytes have a high density of the asialo-glycoprotein receptor (ASGP-R) (500,000 receptors per cell) and easily binds carbohydrates such as galactose, mannose, arabinose which can effectively act as liver-targeted drug delivery systems (Shen, Wei, Tanaka, Kohama, Ma, & Dobashi, 2011); (Kim, Jeong, & Moon, 2005)(Yang, Zhang, Chen, Gu, & Li, 2010); (Cho & Park, 2008).

2.2.4.3 Riboflavin

An essential vitamin for cellular metabolism is riboflavin and thus, the carrier protein of riboflavin (RCP) is highly upregulated in metabolically active cells (Foraker, Khantwal, &

Swaan, 2003). Therefore, an endogeneous RCP ligand known as the flavin mononucleotide (FMN), was used for the metabolically active cancer or endothelial cells (Karande, Sridhar, Gopinath, & Adiga, 2001). FMN- coated ultra-small super paramagnetic iron oxide nano particles (FLUSPIO) synthesized by Kiessler and co-workers to be used as MRI/optical dual probes for cancer detection which was stabilized by guanosine monophosphate (Jayapaul, Hodenius, Arns, Lederle, Lammers, & Comba, 2011). An intense fluorescence emission was observed at 530 nm due to FMN. Through MRI, TEM and fluorescence microscopy of PC3 cells and HUVEC cells the cellular uptake of FLUSPIO was investigated in vitro. After 1 hour incubation with FLUSPIO and non-targeted USPIO, both PC3 and HUVEC cells depicted a higher R2 relaxation rate. This uptake was reduced by the competitive blocking of RCP with free FMN. After the incubation period, a green fluorescence in the cells was observed. This suggested that since there was endosomal localization of the nanoparticles indicating that FMN could be considered as a building block for imaging and therapeutic agent for tumors. (Yu, Park, & Jon, 2012)

2.2.4.4 Epidermal Growth Factors

The EGFRs are part of a group of tyrosine kinase receptors. These receptors are highly upregulated on tumor cell surfaces. EGFR binds to six known endogenous ligands, namely: EGF, transforming growth factor-α, amphiregulin, betacellulin, heparin-binding EGF, and epiregulin(Laskin & Sandler, 2004). When EGFR is activated by one of these ligands intracellular signaling processes are stimulated which increases tumor growth and progression involving multiplication, angiogenesis, invasion, and metastasis. Overexpression of EGFR is evident in breast, lung, colorectal, and brain cancers (Acharya, Dilnawaz, & Sahoo, 2009).

2.2.4.5 Transferrin

Transferrin is a serum non-heme iron-binding glycoprotein which acts as a transporter which aids in the transport of iron through blood and into proliferating cells by its attachment to the transferring receptor. When the transferrin internalizes via receptor mediated endocytosis, iron is released in the acidic environment of the cell. The receptor is very important since it is responsible for iron homeostasis and regulation of cell growth. Therefore, due to the increased demand for iron as compared to the normal cells, transferrin receptors are overexpressed in metastatic and drug resistant cancer cells which make them an attractive target for cancer therapy and tumour-specific drug delivery.(Cho, Wang, Nie, Chen, & Shin,

2008);(Pastorino, Brignole, & Di Paolo, 2006);(Daniels, Delgado, Helguera, & Penichet, 2006)Transferrin-conjugated paclitaxel loaded [poly(lactic-co-glycolic-acid) polymer] nanoparticles inhibited cell growth to a greater extent compared to free paclitaxel (Sahoo & Labhasetwar, 2005). Transferrin conjugated to liposomes promoted transfection efficacy of glycoprotein p53 leading to sensitization of transfected cancer cells (Xu, Pirollo, Tang, Rait, & Chang, 1999).

2.2.4.6 Lectins

Lectins are proteins that are able to identify and bind specifically to the carbohydrate moieties of glycoproteins present on the extracellular side of plasma membrane. The glycoproteins of cancer cells are different from the ones expressed on the normal cells (Prabhu, Patravale, & Joshi, 2015). Therefore, lectins can be used as targeting molecules for site-specific delivery of drugs (Cho, Xu, Shuming, Chen, & Shin, 2008).

Lectin targeting based on lectin-carbohydrate interaction can be characterized into two types, known as direct lectin targeting and reverse lectin targeting (Cho, Xu, Shuming, Chen, & Shin, 2008); (Prabhu, Patravale, & Joshi, 2015). Direct lectin targeting incorporates lectins into nanoparticles as ligand to target cell surface carbohydrates and reverse lectin targeting that involves conjugating nano-system with carbohydrate moiety to target lectins(Cho, Xu, Shuming, Chen, & Shin, 2008). Lectin based targeting is primarily applied for targeting colon (Minko, 2004).

Chapter 3

TYPES OF POLYMER BASED NANOCARRIERS FOR TARGETED CANCER THERAPY

3. TYPES OF POLYMER BASED NANOCARRIERS FOR TARGETED CANCER THERAPY

The greater scope of chemically modifying the polymeric system has increased its potential to be utilized for targeted drug delivery of many therapeutic agents especially for the treatment of cancer. The therapeutic agent is either conjugated to the surface of the nanoparticle or can be encapsulated within the polymeric core. The polymers used for the development of these nanocarriers may be either natural or synthetic (Prabhu, Patravale, & Joshi, 2015). These polymeric nanoparticles offer numerous advantages for drug delivery by enabling high loading efficiencies and ability to target tumors to provide enhanced antitumor efficacy through triggered release inside tumors with minimum side effects (Cho, Xu, Shuming, Chen, & Shin, 2008). Additionally, these nanoparticles provide a shielding effect by protecting the drugs from rapid clearance by liver, kidney and reticulo-endothelial system which enhances stability of the drug and target specificity (Prabhu, Patravale, & Joshi, 2015); (Cho, Xu, Shuming, Chen, & Shin, 2008). The polymeric nanoparticles can be classified as solid polymeric nanoparticles, polymeric micelle, polymer conjugate, dendrimer, polymersome, polyplex and polymer-lipid hybrid system (Figure 2) (Prabhu, Patravale, & Joshi, 2015). The different types of nanoparticles characterized by their unique physicochemical structures and their applications in the treatment of cancer have been discussed in the following sections.

Figure 3.1: Schematic illustration of polymeric nanoparticles platforms (Prabhu, Patravale, & Joshi, 2015).

3.1 Polymeric Nanoparticles

Polymeric nanoparticles are solid colloidal systems in which the therapeutic agent is either dissolved, entrapped, encapsulated or adsorbed onto the constituent polymer matrix(Prabhu, Patravale, & Joshi, 2015). The structures of polymeric nanoparticles depend on the process of formation of nanoparticles and vary from nanospheres to nanocapsules (Figure 3). Nanospheres are matrix systems in which the drug is dispersed throughout the particles whereas nanocapsules refer to vesicles in which the drug is entrapped within an aqueous or oily cavity which is further surrounded by a monolayer of polymeric membrane (Parveen & Sahoo, 2008);(Letchford , Burt, & Vroman, 2007).

A wide range of polymers can be used to fabricate polymeric nanoparticles which includes natural or synthetic substances composed of macromolecules such as poly (lactide-coglycolide), polyethylene glycol, poly (lactic acid), poly(ϵ -caprolactone), albumin, chitosan, and poly (alkyl cyanoacrylates) (Kiman & Van Der, 2010). The composition of the nanoparticles varies for the delivery of specific drugs to the surface of specific cells (Bian, Lu, Xu, Fanand, & Zhang, 2014).The first step for using a polymeric carrier is to ensure that the polymeric structure is biodegradable and can retain its properties *in vivo* for a prolonged period of time. Biodegradability is a critical factor so that polymeric carriers are degraded into smaller fragments that can be metabolized and excreted from the body. In comparison with other drug delivery systems, polymeric nano-carriers are non-toxic, non-immunogenic, relatively easier to synthesize, cheaper, water soluble and provide better biodegradability and biocompatibility (Chen, Chan, Wu, & Chen, 2015).

A nanoparticle formulation of paclitaxel which contains serum albumin as a carrier, commercially known as Abraxane, has been used for the treatment of metastatic breast cancer (Gradishar, Tjulandin, & Davidson, 2005). Abraxane has not only been used for metastatic breast cancer but also has been assessed in other clinical trials for non-small-cell lung cancer (Phase II trial) and advance non-hematologic malignancies (Phase I and pharmacokinetics trials) (Cho, Xu, Shuming, Chen, & Shin, 2008).

Nanoparticles loaded with paclitaxel (PTX) and tamoxifen (TMX) containing biodegradable polyethylene oxide (PEO) conjugated with poly (ϵ -caprolactone) (PCL) proved to be efficient in overcoming multidrug resistance in the treatment of ovarian adenocarcinoma. Substantial enhancement in antitumor efficacy was observed and there was hardly any

toxicity associated upon intravenous administration of nanoparticulate formulations of PTX-TMX in combination with PEO-PCL (Devalapally, Duan, Seiden, & Amiji, 2008).

An aptamer-functionalized poly (lactide-coglycolide) conjugated with polyethylene glycol (PLGA-PEG) nanoparticles was developed against prostate-specific membrane antigen (PSMA) overexpressing cancer cells by Cheng et al. The delivery of the nanoparticles to the tumours was increased by 3.77 fold in 24 hours compared to nanoparticles without the aptamer(Cheng, Su, Wu, & Yeh, 2010).A list of the polymers used to develop polymeric nanoparticles and employed for passive and ligand based delivery of drugs to treat various types of cancers are shown in Table 1 and Table 2.

Figure 3.2: Structures of different types of biodegradable polymeric particles (nanospheres and nanoparticles. (Kumari, Yadav, & Sudesh, 2010).

3.2 Polymeric Micelles

Polymeric micelles are formed as a result of self-assembling of amphiphilic di- or tri- block copolymers into spherical nanosizedcore/shell structure in aqueous media(Cho, Xu, Shuming, Chen, & Shin, 2008).The hydrophobic core acts as a reservoir for hydrophobic drugs and allows for encapsulation of anticancer drugs whereas the hydrophilic shell is responsible for stabilizing the hydrophobic core which makes the polymer water-soluble and an attractive

drug delivery system for intravenous route of administration. The hydrophilic layer also provides stealth property to the system which prolongs the circulation time of the micelle in the blood as it averts the uptake by the reticulo-endothelial system (Cho, Xu, Shuming, Chen, & Shin, 2008);(Prabhu, Patravale, & Joshi, 2015). The micelles that are derived from polymer have greater stability and lower critical micellar concentration value(in order of 10^{-6} M) when compared to surfactant-based micelles (Sutton , Nasongka, Blanco, & Gao, 2007); (Oerlemans, Bult, Bos, Storm, Nijsen, & Hennink, 2010).The loading of the drug within the micelle can be carried out in two ways -physical encapsulation and chemical covalent attachment (Nakanishi, Fukushima, & Okamoto, 2001).

Recent studies on few of the micellar based anticancer drugs have shown their potential as drug carriers in oncotherapy(Oerlemans, Bult, Bos, Storm, Nijsen, & Hennink, 2010).

Genexol-PM (PEG-poly(D,L-lactide)-paclitaxel) is the first polymeric micelle formulation of paclitaxel. It is cremophor-free (i.e. free from poly-ethoxylated castor oil which is used in other formulations of paclitaxel). This particular polymeric micelle formulation has undergone Phase I and pharmacokinetic studies in patients with advanced refractory diseases (Kim, Kim , & Chung, 2004). Multifunctional polymeric micelles coupled with targeting ligands and imaging and therapeutic agents are being developed as well (Nasongka, Bey, Ren, Ai, & Khemtong, 2006).

Curcumin was encapsulated using polymeric micelles of cross-linked and random copolymers of N-isopropylacrylamide with N-vinyl-2-pyrrolidone and PEG monoacrylate. Anticancer efficacy was observed *in vitro* when compared with free curcumin against human pancreatic cancer cells lines by these newly formulated micelles (Bisht, Felmann, & Soni, 2007).

Cisplatin incorporated within PEG-polyglutamic acid block copolymer micelles showed 20-fold higher blood circulation and accumulation in solid tumors compared to free cisplatin in lung carcinoma cells. It provided sufficient stability that led to prolonged circulation and showed sustained drug release pattern after accumulation at the delivery site through enhanced permeability retention effect. Furthermore, complete destruction of the tumor occurred and no significant loss in body weight was observed after treatment with polymeric micelles compared to free cisplatin which causes approximately 20 percent loss of body weight and tumor survival at an equivalent dose (Nishiyama, Okazaki, & Cabral, 2003).

Polymeric micelles consisting of PEG-phosphatidyl ethanolamine conjugated to antitumor monoclonal antibody that had a nucleosome-restricted specificity for different cancer cells were developed for target-specific delivery of Paclitaxel (PTX). These immune micelles were able to recognize and efficiently bind to various cancer cells such as the murine lung carcinoma cells, lymphoma cells and human breast adenocarcinoma cell lines *in vitro*. The tumor specific immune-micelles loaded with PTX demonstrated an increase in accumulation of PTX in the tumor and enhanced the inhibition of the growth rate of the tumor upon intravenous administration into mice with lung carcinoma by a factor of 2.5 times compared to free PTX or TAXOL in non-targeted micelles. (Torchilin, Lukyanov, Gao, & Papahadjopoulos-Sternberg, 2003)

Folic acid was coupled with doxycycline loaded PEG-PLGA micelles by covalently attachment of the ligand through its γ -carboxyl group to form polymeric micelles. Enhanced cellular uptake as well as cytotoxicity against human nasopharyngeal epidermal carcinoma cell lines was observed in comparison to non-targeted micelles. In addition, there was a two times reduction in the rate of tumor growth showing significant improvement in antitumor activity in contrast to non-targeted micelles. (Yoo & Park, 2004)

In order to overcome multidrug resistance (MDR) in human breast cancer, pluronic copolymers were studied as micellar carriers for delivery of Paclitaxel. Pluronic micellar paclitaxel resulted in a remarkable decrease in IC_{50} of Paclitaxel in multidrug resistance cell lines when compared with free Paclitaxel, thus proving its potential to cause cytotoxic effects in multidrug resistance cells compared to nonresistant cell lines. Enhanced uptake by the folate receptors led to greater internalization of the polymeric micelles and therefore pluronics based micelles to overcome MDR and folate-mediated uptake can be applied for the treatment of MDR solid tumours (Wang, Yu, Han, Sha, & Fang, 2007).

3.3 Dendrimers

A dendrimer is a synthetic polymeric macromolecule of nanometer dimensions. They are composed of repeatedly branched monomers that extend from the central core resembling a tree-like structure. (Cho, Xu, Shuming, Chen, & Shin, 2008); (Prabhu, Patravale, & Joshi, 2015)

They can serve as attractive carriers for anticancer therapeutics because of their distinct properties such as mono-disperse size, modifiable surface functionality that facilitates the

encapsulation/ conjugation of therapeutic agent in the internal cavity or on the surface multivalency as well water solubility (Svenson & Tomalia, 2005).

Poly (glycerol succinic acid) dendrimers were investigated as potential carriers for Campotothecin. Camptothecin encapsulated dendrimer exhibited anticancer activity which was assessed by using the human breast adenocarcinoma (MCF-7), colorectal adenocarcinoma (HT-29), non-small-cell lung carcinoma (NCI-H460), and glioblastoma (SF-268). When compared to camptothecin dissolved in dimethyl sulfoxide, the dendrimer carrier camptothecin demonstrated an increased cytotoxity as well as a decrease in IC_{50} in two-to-seven-fold range. Cellular uptake was also increased by 16-fold compared to the free drug in MCF-7 cells (Morgan, Carnahan, & Finkelstein, 2005); (Morgan, Nakanishi, & Kroll, 2006). Melamine based dendrimers reduced the organ toxicity of anticancer agents such as methotrexate and 6-mercapturine which causes hepatotoxicity. Alanine transaminase level ALT) was reduced to 27 percent in case of methotrexate encapsulated dendrimers, while for 6-mercaptopurine was reduced to 36 percent as compared to the non-encapsulated drugs (Neerman, Chen, Parrish, & Simanek, 2004).

Poly (ε - caprolactone) and polyethylene glycol (PEG) were explored as a carrier for the anticancer drug etoposide and showed comparable toxicity to free etoposide when tested on porcine kidney cells.

The dendrimer most widely used as a scaffold is poly-amido amine dendrimer. A polyamidoamine (PAMAM) dendrimer was conjugated with cisplatin formed by sodium carboxylate synthesizing dendrimer platinate which released platinum slowly in vitro. The dendrimer Pt was 8-fold less toxic than the free drug and showed higher activity against melanoma bearing mice when compared to the free drug upon intraperitoneal administration. Free Cisplatin was inactive after IV administration to treat melanoma whereas the dendrimer-Pt showed anticancer activity (Malik, Evagorou, & Duncan, 1999).

3.4 Polymersomes

Polymer vesicles composed of synthetic amphiphilic block copolymers that are self-assembled and contain separate hydrophilic and hydrophobic blocks are known as polymersomes. They are similar to liposomes in terms of architecture and structured design but have greater stability, storage capability and enhanced circulation time compared

liposomes even though structurally they are similar (Levine, Ghoroghchian, & Freudenberg, 2008).

Doxycycline (DOX) can be encapsulated within the aqueous center of the polymer vesicles. The efficiency of DOX-loaded PEO-block-PCL in terms of its therapeutic activity was studied in xeno-transplanted tumor-bearing mice and their potential to retard tumour growth was assessed. When compared to commercially available DOXIL, which is a clinically administered liposomal formulation of DOX, DOX-loaded polymersomes were able to inhibit the tumor growth in a similar manner (Levine, Ghoroghchian, & Freudenberg, 2008).

For breast cancer therapy polymersomes based on phosphazene were researched on as the delivery systems of hydrophilic DOX hydrochloride or hydrophobic DOX base which allowed higher encapsulation of DOX or DOX-HCl. In comparison to free DOX-HCL, the DOX-HCL loaded polymersomes increased life safety upon in vivo administration of these polymersomes in mice with xenograft tumors (Xu, Zhao, Jin, & Qiu, 2014). Efficient passive delivery to human breast tumor-bearing mice can be obtained by co-encapsulation of PTX (in hydrophobic bilayer) and DOX (in hydrophilic core) by utilizing polymersomes. The dual drug loaded polymersome increases the synergistic anticancer effect, increases the suppression of the tumor and also shows a higher maximum tolerated dose as compared to the free drug (Ahmed, Pakunlu, Brannan, Bates, Minko, & Discher, 2006); (Ahmed, Pakunlu, & Srinivas, 2006).

Bio-resorbable polymersomes were developed for efficient and targeted delivery of cisplatin to human colon cancer cells that overexpress $\alpha(5)\beta(1)$ integrin (Rodrigues, 2003).

PEO-block-poly(ɣ -methyl-ε -caprolactone) polymersomes were attached with $\alpha(5)\beta(1)$ integrin specific targeting peptide named PR_b which enabled target binding and enhanced uptake into the cancer cells. As a comparison to the conventional RGD-targeting peptides which bind to different types of integrins. Higher cytotoxity was observed in colon cancer cells.

Self-assembled polymersomes from PEO-b-poly(butadiene) di-block copolymers functionalized with PR_b employed for delivery of therapeutic protein named tumor necrosis factor-α(TNF-α) to prostate cancer cells. PR_b polymersomes attached to the $\alpha_5\beta_1$ integrins which were expressed on prostate cancer cells led to efficient internalization of

polymersomes and enhanced cytotoxic potential compared with non-targeted polymersomes(Demirgoz, Pangburn, Davis, Lee, Bates, & Kokkoli, 2009).

3.5 Polyplexes

Polymeric systems which formed as a consequence of condensation and/or complexation of gene or siRNA through electrostatic interactions between the cationic groups of the polymer and the negatively charged nucleic acids are termed as polyplexes. The nucleic acids are protected from enzymatic degradation by the polyplexes and prevent the release at off-target sites. Transfection with the negatively charged cell surface may be enhanced by the polyplexes which contain an excess of positive charge. Site-specific delivery of therapeutic nucleic acids to the tumor sites is a promising strategy for the treatment of cancer (Christie, Nishiyama, & Kataoka, 2010).

Poly-l-lysine based vector was investigated for cancer-specific gene therapy by modifying the polymer (Zhao, Tanaka, & Kim, 2014). In order to impart endosome escape property, the polymer was modified with histidine group and with cationic peptide moiety to help in the formation of polyplex with pDNA and act as a substrate for protein kinase (α(PK(α) which is specifically activated in cancer cells. After application of the polyplexes into cancer cells, protein kinase responsive gene expression was observed which extended for 24 hours (Chen, Wang, Zhang, Wang, Hu, & Ji, 2013).

Polyplexes using phosphorylcholine-modified polyethyleneimine (PEI) has been utilized for efficient delivery of DNA in cancer therapy. These polyplexes enabled selective uptake by the liver cancer cells compared to PEGylated polyplexes and showed gene expression in liver cancer cells six folds greater than normal cells (Esmaili, 2008).

The ability of galactose-modified trimethyl chitosan-cysteine-based polymeric vectors to deliver siRNA were explored. The result showed that the polyplexes were efficient in persistent gene knockdown when in human liver cancer and human lung cancer cells. In addition, greater retardation of tumour growth, angiogenesis inhibition and apoptosis induction was observed with the use of these polyplexes(Sheng, 2009). For the delivery of prostate cancer cell-specific VEGF siRNA, a polymeric system was developed in which PEI was joined with the prostate cancer cell-targeting peptide by a PEG linker, to form stable polyplexes by condensing siRNA. Higher gene silencing ability was demonstrated by these

newly formed polyplexes because of targeting peptide-mediated specific internalization in human prostate carcinoma cells (Kim, Lee, Tian, Chen, & Park, 2009).

3.6 Polymer hybrid systems

3.6.1 Polymer-lipid hybrid system

When polymeric nanoparticles and liposomes are enjoined together, the resulting system is known as polymer-lipid hybrid system. The polymer-lipid hybrid system is composed of a biodegradable hydrophobic polymeric core that encapsulates water- soluble anticancer drugs for sustained-release action, which is surrounded by a hydrophilic shell responsible for providing stealth property that prevents them from recognition by the immune system and prolongs the systemic circulation. A third component known as the lipid monolayer is also present as part of the system that separates the hydrophobic core and hydrophilic shell to prevent diffusion of encapsulated agent and reduce the rate of water penetration into the nanoparticles. This hybrid system offers the advantages of both the polymeric nanoparticles and liposomes which are greater amount of drug encapsulation and loading efficiency, desirable sustained release drug profile, better stability and enables surface functionalization for targeting cancer cells (Zhang, Chan, & Gu, 2008).

An example of a polymer-lipid hybrid system is complexation of cationic doxorubicin with anionic soybean-oil-based polymer dispersed with lipid (stearic acid) in water (Wong, Rauth, & Bendayan, 2006). This particular hybrid system exhibited effective delivery of the anticancer drug doxorubicin and enhanced cytotoxicity by eight-fold against P-gp-overexpressing human breast cancer cell line. Furthermore, the incorporation of doxorubicin within the polymer-lipid hybrid nano-particulate showed enhanced uptake of the drug and retention in P-gp-overexpressing cells than free drug (Wong, Bendayan, Rauth, Babakhanian, & Wu, 2006).

3.6.2 Polymer-surfactant hybrid system

Surfactants are agents that are responsible for reducing interfacial tension between two or more components in a system, thus promoting miscibility, colloidal stability, dispersion between water and oil, nanoparticles and polymers, nanoparticles and analytes(Heinz, et al., 2017). A polymer-surfactant nano-particulate hybrid system was developed by Chavanpatil et al. that comprised of sodium alginate as the polymer and dioctyl sodium sufosuccinate as the anionic surfactant. The hybrid system resulted in enhanced cytotoxicity as a result of

increased cellular uptake and drug accumulation in drug-resistant cells compared to doxorubicin solution (Chavanpatil, Khdair, & Gerard, 2007).

3.6.3 Polymer cyclodextrin hybrid system

Cyclodextrins are glucopyranose units which are linked with α bonds (Duchene, Ponchel, & Wouessidjewe, 1999);(Memisoglu-Bilensoy, Trichard, Bochot, Hincal, & Duchene, 2005).The natural cyclodextrins are named as α, β, γ, based on the number of glucopyranose units, for example α cyclodextrins contain 6 units of glucopyranose and β and γ cyclodextrins contain 7 and 8 units respectively.

Cyclodextrins have a truncated cone shaped appearance and are polar exterior owing to the presence of primary and secondary hydroxyls groups as shown in Figure 4.The interior of the cyclodextrins is apolar which enables them to incorporate hydrophobic molecules within the cavity and form an inclusion complex in the molar ratio 1:1, 1:2 or 2:1 drug: cyclodextrin. Various physicochemical properties, such as the taste, solubility, stability, odor, side effects and physical state of the guest molecule can be altered using this cyclodextrin inclusion complex. Therefore, cyclodextrins has been widely used as excipients since it improves solubility of poorly water soluble drug, enhances the physical or chemical stability of active ingredient and avoids the side effects of drugs in parenteral, oral, nasal, buccal, topical and mucosal formulations (Duchene, Ponchel, & Wouessidjewe, 1999);(Duchene, Wouessidjewe, & Ponchel, 1999);(Thompson, 1997).

It seems a promising approach to formulate nanoparticles directly from cyclodextrins owing to the idea that cyclodextrins with amphiphilic property self-assemble at interfaces. Since natural or hydrophilic cyclodextrins are being used in nanoparticles as coating material or in conjugation with polymers for the controlled release of drugs, amphiphilic cyclodextrins could also be used individually as a nanoparticle. Even though amphiphilic cyclodextrins can be acquired by the chemical grafting of long aliphatic chains to the primary and /or secondary faces with ester, ether, thio, fluoro or amido bonds, they can still form inclusion complexes with lipophilic drugs. Cyclodextrins can also form nanoparticle by techniques such as nanoprecipitation, double emulsion and detergent dialysis techniques(Fessi, Devissaguet, Puisieux, & Thies, 1997);(Wouessidjewe, Skiba, Leroy-Lechat, & Duchene, 1996);(Lemos-Senna, Wouessidjewe, Lesieur, & Duchene, 1998).

A transferrin-modified, cyclodextrin polymer-based system for delivery of siRNA was formulated by Bellocqet et al. The hybrid system is composed of a cyclodextrin polycation condensed with nucleic acid along with the presence of polyethylene glycol at the surface for increasing the stability in biological fluids as well as transferrin used for targeting of cancer cells. The conjugate transferrin-PEG-adamantane self assembles with the nanoparticles by adamantane(host) and cyclodextrin (guest) inclusion complex formation, resulting in a a four-fold enhancement of leukemia cells compared to non-targeted nanoparticles (Bellocq, Pun, Jensen, & Davis, 2003).

Figure no. 3.3: Schematic diagram of natural cyclodextrins and its modification sites.

3.6.4 Polymer conjugates

Polymer conjugates refer to water-soluble polymers either conjugated to anticancer drugs or proteins. They are considered as new chemical entities as they have a pharmacokinetic profile which differs from that of the parent drug (Prabhu, Patravale, & Joshi, 2015). Protein used carrier systems provide selective drug targeting and solves enzyme-induced degradation problem, thus increasing stability (Chen, Chan, Wu, & Chen, 2015). Proteins also offer numerous advantages such as decreased immunogenicity, greater plasma half-life and prolonged systemic circulation (Prabhu, Patravale, & Joshi, 2015).

Polymer-drug conjugation promotes tumour targeting using the phenomenon of EPR effect and enables endocytic capture at cellular level, culminating in lysosomotropic drug delivery (Prabhu, Patravale, & Joshi, 2015). A targeting moiety or inclusion of a targeting ligand or antibody in polymer drug conjugate allows for specific targeting of tumours(Cho, Xu, Shuming, Chen, & Shin, 2008).

Internalization usually takes place through receptor-mediated endocytosis. For example, an endosome is formed after the invaginating plasma membrane engulfs the complex of the folate-targeted conjugate bound with the folate receptor on the cell surface. These endosomes are then transferred to target different organelles. The drug is released from the conjugate when the interior pH value of the endosome becomes acidic and the lysozymes are activated. Given that the drug has the suitable physic-chemical properties to cross through the endosomal membrane, it enters the cytoplasm. The released drugs are then taken up by their preferred target organelle. During this time, the folate receptor which was released from the conjugate starts a second round of transporting by binding to new folate-targeted conjugates by returning to the cell membrane (Leamon & Reddy, 2004).

The polymers used in the fabrication of polymer-drug conjugates include linear polymers such as N-(2-hydroxypropyl) methacrylamide copolymers, polyglutamic acid, PEG and polysaccharides (dextran) with drugs (DOX, PTX, camptothecin and platinate). The clinically approved polymeric nanoparticles used for oncologic treatment are listed in Table 1.

Table 1: Clinically approved polymeric nanomedicine for oncologic treatment.

Polymeric Platforms	Product Description	Therapeutic Agent	Commercial Name	Indication	Administration
Polymer-protein conjugate	SMANCS	Neocarzinostatin	ZinostatinStimalmer	Hepatocellular carcinoma	Intra-arterial
	PEG-l asparaginase	Asparaginase	Oncaspar	Acute lymphoblastic leukemia	Intravenous, intramuscular
	PEG-GCSF	GCSF	Neulasta/PEG/Algrastim	Prevention of neutropenia associated with cancer chemotherapy	Subcutaneous
Polymeric micelle	Methoxy-PEG-poly (d,l-lactide)-paclitaxel micelle	Paclitaxel	Genexol-PM	Metastatic breast cancer	Intravenous

Chapter 4

CONCLUSION

4.1 CONCLUSION

Advances in the field of polymeric nanoparticles is rapidly progressing and offers new opportunities for targeted treatment of cancer. The targeted delivery of nanoparticles can overcome the problems associated with the conventional cancer therapy such as lack of water solubility, nonspecific biodistribution and lack of selectivity resulting in non- specific toxicity towards normal cells and lower dose of drugs delivered to cancer cells leading to poor bioavailability and low therapeutic indices (Cho, Xu, Shuming, Chen, & Shin, 2008); (Yu, Park, & Jon, 2012). The nanoparticles can be designed for optimal size and surface characteristics to prolong their circulation time in the bloodstream to improve the biodistribution of cancer drugs (Cho, Xu, Shuming, Chen, & Shin, 2008). Various polymers are currently being explored to modify the properties of polymeric matrix which enables greater encapsulation efficiency and high therapeutic load with controlled release ability for the treatment of cancer (Prabhu, Patravale, & Joshi, 2015). Passive and active targeting strategies are used to deliver drugs to the target sites. Nanoparticles can utilize the enhanced permeability and retention effect and the tumour microenvironment to selectively target the anticancer drug to the cancer cells. In addition to this passive targeting mechanism, active targeting strategies using ligands and antibodies can increase the specificity of these therapeutic nanoparticles (Yu, Park, & Jon, 2012). Nanoparticles can be used to decrease or overcome drug resistance which hinders the efficiency of molecularly targeted and conventional chemotherapeutic agents by escaping recognition from P- glycoprotein, one of the main mediators of multidrug resistance. (Cho, Xu, Shuming, Chen, & Shin, 2008). Moreover, progression in nanoscale imaging allows for the development of multifunctional "smart" nanoparticles that can facilitate personalized cancer therapy as they are capable of detecting malignant cells (active targeting moiety), visualizing of their location in the body (real-time *in vivo* imaging), destroying the cancer cells specifically and harming the normal cells leading to minimum side effects (active targeting and controlled drug release) and monitoring the outcome of treatments in real time (Cho, Xu, Shuming, Chen, & Shin, 2008). Although, a number of polymeric nanoparticles have been clinically approved for oncologic treatment, yet these nanoparticles for functionalization with targeting ligand must be evaluated and the safety of these nanocarriers must be assessed before proceeding to clinical study (Prabhu, Patravale, & Joshi, 2015).

References

Acharya, S., Dilnawaz, F., & Sahoo, S. (2009). Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy. *Biomaterials* , 5737-5750.

Ahmed, F., Pakunlu, R., & Srinivas, G. e. (2006). Shrinkage of a rapidly growing tumor by drug loaded polymersomes:pH triggered release through copolymer degradation. *Mol. Pharm.* , 340-350.

Ahmed, F., Pakunlu, R., Brannan, A., Bates, F., Minko, T., & Discher, D. (2006). Biodegradable polymersomes loaded with both paclitaxel and doxorubicin permeate and shrink tumors, inducing apoptosis in proportion to accumulated drug. *J. Control Release* , 150-158.

Aime, S., Barge, A., Cabella, C., Crich, S., & Gianolio, E. (2004). Targeting cells with MR imaging probes based on paramagnetic Gd(III) chelates. *Curr. Pharm. Biotechnol.* , 509-518.

Albanell, J., & Baselga, J. (1999). Trastuzumab. A humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer. *Drugs Today* , 931-946.

Asati, A., Santra, S., Kaittanis, C., & Perez, J. (2010). Surface-charge dependentcell localization and cytotoxicity of cerium oxide nanoparticles. *ACS Nano.* , 5321-5331.

Bagalkot, V., Farokhzad, O., Langer, R., & Jon, S. (2006). An aptamer doxorubicin physical conjugate as a novel targeted drug-delivery platform. *Angew Chem. Int. Ed.* , 8149-8152.

Barth, R., & Soloway, A. (1994). Boron neutron capture therapy of primary and metastatic brain tumors. *Mol. Chem. Neuropathol.* , 139-154.

Bates, P., Kahlon, J., Thomas, S., Trent, J., & Miller, D. (1999). Antiproliferative activity of G-rich oligonucleotides correlates with protein binding. *J. Biol. Chem.* , 113.

Bates, P., Laber, D., Miller, D., Thomas, S., & Trent, J. (2009). Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. *Exp. Mol. Pathol.* , 114.x

Beekman, K., Colevas, A., Cooney, K., Dipaola, R., Dunn, R., & Gross, M. e. (2006). Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design. *Clin. Genitourin Cancer* , 299-302.

Beh, C., Seow, W., & Wang, Y. e. (2009). Efficient delivery of Bel-2-targeted siRNA using cationic polymer nanoparticles. *Biomacromolecules* , 41-48.

Bellocq, N., Pun, S., Jensen, G., & Davis, M. (2003). Transferrin-containing,cyclodextrin polymer-based particles for tumor-targeted gene delivery. *Bioconjug. Chem.* , 1122-1132.

Bharali, D., Khalil, M., Gurbuz, M., Simone, T., & Mousa, S. (2009). Nanoparticles and cancer therapy: concise review with emphasis on dendrimers. *Int. J. Nanomedicine* , 1-7.

Bian, S., Lu, W., Xu, C., Fanand, Y., & Zhang, X. (2014). In vitro cartilage tissue engineering using porous collagen/PLLA nanoparticle hybrid scaffold. *Journal of Medical and Biological Engineering* , 36-43.

Bisht, S., Felmann, G., & Soni, S. e. (2007). Polymeric nanoparticle-encapsulated curcumin("nanocurcumin"): a novel strategy for human cancer therapy. *J Nanobiotechnology* , 3.

Bouchard, P., Hutabarat, R., & Thompson, K. (2010). Discovery and development of therapeutic aptamers. *Annu. Rev. Pharmacol. Toxicol.* , 237-257.

Boyer, C., Teo, J., & Phillips, P. e. (2013). Effective delivery of siRNA into cancer cells and tumors using well-defined biodegradable cationic star polymers. *Mol. Pharm* , 2435-2444.

Brewer, E., Coleman, J., & Lowman, A. (2011). Emerging technologies of polymeric nanoparticles in cancer drug delivery. *J Nanomater* , 1-10.

Byrne, J., Betancourt, T., & Brannon-Peppas, L. (2008). Active targeting schemes for nanoparticle systems in cancer therapeutics. *Adv. Drug Deliv. Rev.* , 1615-1626.

Carmeliet, P., & Jain, R. (2000). Angiogenesis in cancer and other diseases. *Nature* , 249-257.

Chan, J., Valencia, P., Zhang, L., Langer, R., & Farokhzad, O. (2010). Polymeric nanoparticles for drug delivery. *Methods Mol. Biol.* , 163-175.

Chan, W., Maxwell, D., Gao, X., Bailey, R., Han, M., & Nie, S. (2002). Luminescent quantum dots for multiplexed biological detection and imaging. *Curr. Opin. Biotechnol.* , 40-46.

Chavanpatil, M., Khdair, A., & Gerard, B. e. (2007). Surfactant-polymer nanoparticles overcome P-glycoprotein-mediated drug efflux. *Mol. Pharm.* , 730-738.

Chen, C., Chan, T., Wu, Y., & Chen, J. (2015). Review: Application of Nanoparticles in Urothelial Cancer of the Urinary Bladder. *J. Med. Biol. Eng* , 419-427.

Chen, J., Saeki, F., & Wiley, B. e. (2005). Gold nanocages: bioconjugation and their potential use as optical imaging contrast agents. *Nano Lett.* , 473-477.

Chen, L., Wang, H., Zhang, Y., Wang, Y., Hu, Q., & Ji, J. (2013). Bioinspired phosphorylcholine-modified polyplexes as an effective strategy for selective uptake and transfection of cancer cells. *Colloids Surf. B. Biointerfaces* , 297-305.

Cheng, F., Su, C., Wu, P., & Yeh, C. (2010). Multifunctional polymeric nanoparticles for combined chemotheraperuic and near-infrared photothermal cancer therapy in vitro and in vivo. *Chem. Commun (Camb)* , 3167-3169.

Cho, C., & Park, I. (2008). Galactosylated poly(ethylene gly-col) chitosan-graft polyethylenimine as a gene carrier for hepatocyte-targeting. *J. Control Release* , 150-157.

Cho, K., Wang, X., Nie, S., Chen, Z., & Shin, D. (2008). Therapeutic nanoparticles for drug delivery in cancer. *Clin. Cancer Res* , 1310-1316.

Cho, K., Xu, W., Shuming, N., Chen, Z., & Shin, D. M. (2008). Therapeutic Nanoparticles for Drug Delivery in Cancer. *Clin Cancer Res* , 1310-1316.

Cho, W. K., & Kim, G. J. (2007). Investigation of Taxol-resistance using folate-targeted ternary therapeutic nanoparticle. *Proc Am Assoc Cancer Res* , 48.

Christie, R., Nishiyama, N., & Kataoka, K. (2010). Delivering the code: polyplex carriers for deoxyribonucleic acid interference therapies. *Endicrinology* , 466-473.

Danhier , F., Lecouturier, N., & Vroman, B. (2009). Paclitaxel loaded PEGylated PLGA based nanoparticles: in vitro and in vivo evaluation. *J Control Release* , 11-17.

Danhier, F., Feron, O., & Preat, V. (2010). To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. *J Control Release* , 135-146.

Daniels, D., Chen, H., Hicke, B., Swiderek, K., & Gold, L. (2003). A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment. *Proc. Natl. Acad. Sci. USA* , 416-421.

Daniels, T., Delgado, T., Helguera, G., & Penichet, M. (2006). The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. *Clin. Immunol.* , 159-176.

Davis, D., Herbst, R., & Abbruzzese, J. (2008). Antiangiogenic Cancer Therapy. *Boca Raton* .

de Campos, W., Coopusamy, D., Morris, L., Mayosi, B., & Khati, M. (2009). Cytotoxicological Analysis of a gp120 binding aptamer with cross-clade human immunodeficiency virus type 1 entry inhibition properties: comparison to conventional antiretrovirals. *Antimicrob. Agents Chemother.* , 56-64.

Dean, H., Wang, C. K., & Hua, E. (2015). Nanodiamonds: The intersection of nanotechnology, drug development and personalized medicine. *Sci. Adv* .

Demirgoz, D., Pangburn, T., Davis, K., Lee, S., Bates, F., & Kokkoli, E. (2009). PR_b-targeted delivery of tumor necrosis factor-α by polymersomes for the treatment of prostate cancer. *Soft Matter* , 2011-2019.

Deryugina, E., & Quigley, J. (2006). Matrix metalloproteinases and tumor metastasis. *Cancer Metastasis Rev.* , 9-34.

Desgrosellier, J., & Cheresh, D. (2010). Integrins in cancer: biological implications and therapeutic opportunities. *Nat. Rev. Cancer* , 9-22.

Devalapally, H., Duan, Z., Seiden, M., & Amiji, M. (2008). Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles. *Clin. Cancer Res.* , 3193-3203.

Dienst, A., Grunow, A., Unruh, M., & al., e. (2005). Specific occlusion of murine and human tumor vasculature by VCAM-1 targeted recombinant fusion proteins. *J. Natl Cancer Inst.* , 733-747.

Dohmen, C., Edinger, D., & Frohlich, T. e. (2012). Nanosized multifunctional polyplexes for receptor mediated siRNA delivery. *ACS Nano.* , 5198-5208.

Drummond, D., K, H., Park, J., Benz, C., & Kirpotin, D. (2000). Liposome targeting to tumors using vitamin and growth factor receptors. *Vitam Horm.* , 285-332.

Duchene, D., Ponchel, G., & Wouessidjewe, D. (1999). Cyclodextrins in targeting. Application to nanoparticles. *Adv. Drug Deliv Rev* , 29-40.

Duchene, D., Wouessidjewe, D., & Ponchel, G. (1999). Cyclodextrins and carrier systems. *J. Control Release* , 263-268.

Duncan, R. (2006). Polymer conjugates as anticancer nanomedicines. *Nat. Rev. Cancer* , 688-701.

Esmaili, F. e. (2008). Folate receptor targeted delivery of docetaxel nanoparticles prepared by PLGA-PEG folate conjugate. *J Drug Target* , 415-423.

Farokhzad, O., Jon, S., Khademhosseini, A., Tran, T., Lavan, D., & Langer, R. (2004). Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. *Cancer Res.* , 68-72.

Ferlay, J., Shin, H. R., Bray, F., & et.al. (2008). Estimates of Worldwide Burden of Cancer in 2008. *Int J. Cancer* , 2893-2917.

Ferrara, N. (2005). VEGF as a therapeutic target in cancer. *Oncology* , 11-16.

Fessi, H., Devissaguet, J., Puisieux, F., & Thies, C. (1997). Process for the preparation of dispersible colloidal systems of a substance in the form of nanoparticles. *U.S. Patent* .

Foraker, A., Khantwal, C., & Swaan, P. (2003). Current perspectives on the cellular uptake and trafficking of riboflavin. *Adv. Drug Deliv. Rev.* , 67-83.

Friedman, A., Claypool, S., & Liu, R. (2013). The smart targeting of nanoparticles. *Curr. Pharm. Des* , 6315-6329.

Gao, X., Yang, L., Petros, J., Marshall, F., Simons, J., & Nie, S. (2006). In vivo molecular and cellular imaging with quantum dots. *Curr. Opin. Biotechnol.* , 63-72.

Genis, L., Galvez, B., Gonzalo, P., & Arroyo, A. (2006). MT1-MMP: universal or particular player in angiogenesis? *Cancer Metastasis Rev.* , 77-86.

Gradishar, W., Tjulandin, S., & Davidson, N. (2005). Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. *J Clin Oncol* , 7794-7803.

Group, T. (2003). Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: Phase II study results. *Ophthalmology* , 979-986.

Gu, F., Karnik, R., & Wang, A. (2007). Targeted nanoparticles for cancer therapy. *Nano Today* , 14-21.

Gupta, A., & Gupta, M. (2005). Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. *Biomaterials* , 3995-4021.

Han, X., Liu, J., & Liu, M. e. (2009). 9-NC-loaded folate-conjugated polymer micelles as tumor targeted drug delivery system: preparation and evaluation in vitro. *Int.J. Pharm.* , 125-131.

Harisinghani, M., Barentsz, J., & Hahn, P. (2003). Noninvasice detection of clinically occult lymph-node metastases in prostate cancer. *New England Journal of Medicine* , 2491-2499.

Heinz, H., Pramanik, C., Heinz, O., Ding, Y., Mishra, R. K., Marchon, D., et al. (2017). Nanoparticle decoration with surfactants: Molecular interactions, assembly, and applications. *Surface Science Reports* , 1-58.

Hu, C., Kaushal, S., & Tran Cao, H. e. (2010). Half-antibody functionalized lipid-polymer hybrid nanoparticles for targeted drug delivery to carcinoembryonic antigen presenting pancreatic cancer cells. *Mol. Pharm.* , 914-920.

James, A., Ambrose, E., & Lowick, J. (1956). Differences between the electrical charge carried by normal and homologous tumour cells. *Nature* , 576-577.

James, J., & Dubs, G. (1997). FDA approves new kind of lymphoma treatment. *AIDS Treat news* , 2-3.

Jayapaul, J., Hodenius, M., Arns, S., Lederle, W., Lammers, T., & Comba, P. e. (2011). FMN-coated fluorescent iron oxide nanoparticles for RCP-mediated targeting and labeling of metabolically active cancer and endothelial cells. *Biomaterials* , 63-71.

Jayasena, S. (1999). Aptamers: An emerging class of molecules that rival antibodies in diagnostics. *Clin. Chem.* , 28-50.

Jeong, Y., Kim do, H., & Chung, C. e. (2011). Doxorubicin incorporated polymeric micelles composed of dextran-b-poly(DL-lactide-co-glycolide) copolymer. *Int. J. Nanomedicine* , 1415-1427.

Jeong, Y., Seo, S., & Park, I. e. (2005). Cellular recognition of paclitaxel-loaded polymeric nanoparticles composed of poly(gamma-benzyl L-glutamate) and poly(ethylene glycol) diblockk copolymer endcapped with galactose moiety. *Int. J. Pharm.* , 151-161.

Jin, X., Mo, R., Ding, Y., Zheng, W., & Zhang, C. (2014). Paclitaxel-loaded N-octyl-O-sulfate chitosan micelles for superior cancer therapeutic efficacy and overcoming drug resistance. *Mol. Pharm.* , 145-157.

Karande, A., Sridhar, L., Gopinath, K., & Adiga, P. (2001). Riboflavin carrier protein: a serum and tissue marker for breast carcinoma. *Int. J. Cancer* , 77-81.

Khati, M. (2010). The future of aptamers in medicine. *Journal of Clinical Pathology* , 480-487.

Kim, E., Jeong, H., & Moon, M. (2005). Asialoglycoprotein receptor targeted gene delivery using galactosylated polyethylenimine graft poly(ethylene glycol): In vitro and in vivo studies. *J. Control Release* , 557-567.

Kim, S., Lee, S., Tian, H., Chen, X., & Park, T. (2009). Prostate cancer cell-specific VEGF siRNA delivery system using cell targeting peptide conjugated polyplexes. *J. Drug Target* , 311-317.

Kim, T., Kim , D., & Chung, J. (2004). Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free polymeric micelle-formulated paclitaxel in patients with advanced malignancies. *Clin. Cancer Res* , 3708-3716.

Kiman, J., & Van Der, B. (2010). The use of nanoparticles in polymeric and ceramic membrane structures: review of manufacturing procedures and performance improvement for water treatment. *Environmental Pollution* , 2335-2349.

Kirpotin, D., Drummond, D., & Shao, Y. (2006). Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. *Cancer Res.* , 6732-6740.

Kohler, N., Sun, C., Wang, J., & Zhao, M. (2005). Methotrexate- modified superparamagnetic nanoparticles and their intracellular upatke into human cancer cells. *Langmuir* , 8858-8864.

Kolishetti, N., Dhar, S., Valencia, P., Lin, L., Karnik, R., & Lippard, S. e. (2010). Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. *Proc. Natl. Acad. Sci. USA* , 39-44.

Krasnici, S., Werner, A., & Eichhorn, M. e. (2003). Effect of the surface charge of liposomes on their uptake by angiogenic tumor vessels. *Int. J. Cancer* , 561-567.

Kumar, M., Yigit, M., Dai, G., Moore, A., & Medarova, Z. (2010). Image-guided breast tumor therapy using a small interfering RNA nanodrug. *Cancer Res.* , 7553-7561.

Kumar, S., & Li, C. (2001). Targeting of vasculature in cancer and other angiogenic diseases. *Trends Immunol.* , 129.

Kumari, A., Yadav, S., & Sudesh, S. (2010). Biodegradable polymeric nanoparticles based drug delivery systems. *Colloids and Surfaces B: Biointerfaces* , 1-10.

Lammers, T., Hennink, W., & Storm, G. (2008). Tumour-targeted nanomedicines: principles and practice. *Br. J. Cancer* , 392-397.

Landsman, M., Kwant, G., Mook, G., & Zijlstra, W. (1976). Light-absorbing properties, stability, and spectral stabilization of indocyanine green. *J. Appl. Physiol.* , 575-583.

Laskin, J., & Sandler, A. (2004). Epidermal growth factor receptor: a promising target in solid tumours. *Cancer Treat Rev.* , 1-17.

Leamon, C., & Reddy, J. (2004). Folate-targeted chemotherapy. *Adv Drug Deliv Rev* , 1127-1141.

Lee, J., Hesselberth, J., Meyers, L., & Ellington, A. (2004). Aptamer Database. *Nucleic Acids Res.* , 95-100.

Lee, J., Stovall, G., & Ellington, A. (2006). Aptamer Therapeutics Advance. *Curr. Opin. Chem. Biol* , 282-289.

Lemos-Senna, E., Wouessidjewe, D., Lesieur, S., & Duchene, D. (1998). Preparation of amphiphilic cyclodextrin nanospheres using the emusion solvent evaporation method, influence of the surfactant on preparation and hydrophobic drug loading. *Int J. Phar.* , 119-128.

Letchford , K., Burt, H., & Vroman, B. (2007). A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes. *Eur. J. Pharm. Biopharm* , 259-269.

Levine, D., Ghoroghchian, P., & Freudenberg, J. e. (2008). Polymersomes: a new multi-functional tool for cancer dianosis and therapy. *Methods* , 25-32.

Lipovsek, D. (2010). Adnectins: engineered target-binding protein. *Protein Engineering, Design & Selection* , 1-9.

Liu, C., & Lin, W. (2012). Polymeric nanoparticles conjugate a novel heptapeptide as an epidermal growth factor receptor-active targeting ligand for doxorubicin. *Int. J. Nanomedicine* , 4749-4767.

Liu, Y., Li, K., Pan, J., Liu, B., & Feng, S. (2010). Folic acid conjugated nanoparticles of mixed lipid monolayer shell and biodegradable polymer core for targted delivery of docetaxel. *Biomaterials* , 330-338.

Loo, C., Lowery, A., Halas, N., West, J., & Drezek, R. (2005). Immunotargeted nanoshells for integrated cancer imaging and therapy. *Nano Lett.* , 709-711.

Lopes de Menezes, D., Pilarski, L., & Allen, T. (1998). In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. *Cancer Res* , 3320-3330.

Low, P., & Antony, A. (2004). Folate receptor-targeted drugs for cancer and inflammatory diseases. *Adv. Drug Deliv. Rev.* , 1055-1058.

Low, P., & Kularatne, S. (2009). Folate-targeted therapeutic and imaging agents for cancer. *Curr. Opin. Chem. Biol.* , 256-262.

Lu, R., Chang, Y., Chen, M., & Wu, H. (2011). Single chain anti-c-Met antibody conjugated nanoparticles for in vivo tumor targeted imaging and drug delivery. *Biomaterials* , 74.

Lupold, S., Hicke, B., Lin, Y., & Coffey, D. (2002). Identification and characterization of nuclease stabilized RNA molecules that bind human prostate cancer cells via the prostate specific membrane antigen. *Cancer Res.* , 4029-4033.

Maeda, H. (2001). The enhanced permeability and retention (EPR) effectin tumor vasculature: the key role of tumor-selevtice macromolecular drug targeting. *Adv. Enzyme Regul.* , 189-207.

Malik, N., Evagorou, E., & Duncan, R. (1999). Dendrimer-platinate: a novel approach to cancer chemotherapy. *Anticancer Drugs* , 767-776.

Mansour, A., Drevs, J., & Esser, N. (2003). A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2. *Cancer Res.* , 4062-4066.

McCarthy, J., Bhaumik, J., Karver, M., Sibel-Erdem, S., & Weissleder, R. (2010). Targeted nanoagents for the detection of cancers. *Mol. Oncol.* , 511-528.

Memisoglu-Bilensoy, E., Trichard, L., Bochot, A., Hincal, A., & Duchene, D. (2005). *Amphiphilic cyclodextrins and microencapsulation.* New York: Taylor and Francis Ltd.

Minko, T. (2004). Drug targeting to the colon with lectins and neoglycoconjugates. *Adv. Drug Deliv. Rev.* , 491-509.

Mongelard, F., & Bouvet, P. (2010). AS-1411, a guanosine-rich oligonucleotide aptamer targeting nucleolin for the potential treatment of cancer, include acute myeloid leukemia. *Curr. Opin. Mol. Ther.* , 107-114.

Morgan, M., Carnahan, M., & Finkelstein, S. e. (2005). Dendritic supramolecular assemblies for drug delivery. *Chem. Commun. (Camb).* , 4309-4311.

Morgan, M., Nakanishi, Y., & Kroll, D. e. (2006). Dendrimer encapsulated camptothecins: increased solubility, cellular uptake,and cellular retention affords enhanced anticancer activity in vitro. *Cancer Res.* , 913-921.

Mukherjee, P., Bhattacharya, R., & Wang, P. (2005). Antiangiogenic properties of gold nanoparticles. *Clin. Cancer. Res.* , 3530-3534.

Nakanishi, T., Fukushima, S., & Okamoto, K. (2001). Development of the polymer micelle carrier system for doxorubicin. *J Control Release* , 295-392.

Nasongka, N., Bey, E., Ren, Ai, H., & Khemtong, C. (2006). Multifunctional polymeric micelles as cancer-targeted, MRI -ultrasensitive drug delivery systems. *Nano Lett* , 2427-2430.

Neerman, M., Chen, H., Parrish, A., & Simanek, E. (2004). Reduction of drug toxicity using dendrimer based on melamine. *Mol. Pharm.* , 390-393.

Nie, Y., Schaffert, D., Rodl, W., Ogris, M., Wagner, E., & Gunther, M. (2011). Dual-targeted polyplexes: one step towards a synthetic virus for cancer gene therapy. *J. Control Release* , 127-134.

Nishiyama, N., Okazaki, S., & Cabral, H. e. (2003). Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice. *Cancer Res.* , 8977-8983.

Nsereko, S., & Amiji, M. (2002). Localized delivery of paclitaxel in solid tumors from biodegradable chitin microparticle formulations. *Biomaterials* , 2723-2731.

Oerlemans, C., Bult, W., Bos, M., Storm, G., Nijsen, J., & Hennink, W. (2010). Polymeric micelles in anticancer therapy: targeting, imaging and triggered release. *Pharm. Res* , 2569-2589.

Oerlemans, C., Bult, W., Bos, M., Storm, G., Nijsen, J., & Hennink, W. (2010). Polymeric micelles in anticancer therapy:targeting, imaging and triggered release. *Pharm. Res.* , 2569-2589.

Oldenberg, S., Jackson, J., Westcott, S., & Halas, N. (1999). Infrared extinction properties of gold nanoshells. *Appl. Phys. Lett.* , 2897-2899.

Osborn, L., Hession, C., Tizard, R., & al, e. (1989). Direct expression cloning of vascular cell adhesion molecule 1, a cytokine induced endothelial protein that binds to lymphocytes. *Cell* , 1203-1211.

Paciotti, G., Myer, L., & Weinreich, D. (2004). Colloidal gold: a novel nanoparticle vector for tumor directed drug delivery. *Drug Delivery* , 169-183.

Padilla De Jesus, O., Ihre, H., Gagne, L., Frechet, J., & Szoka, F. (2002). Polyester dendritic systems for drug delivery applications: in vitro and in vivo evaluation. *Bioconjug Chem.* , 453-461.

Pagratis, N., Bell, C., Chang, Y.-F., Jennings, S., Fitzwater, T., & Jellinek, D. e. (1997). Potent 2[prime]amino, and 2[prime]-fluoro-2[prime]- deoxyribonucleotide RNA inhibitors of keratinocyte growth factor. 68-73.

Park, E., Lee, S., & Lee, Y. (2005). Preparation and characterization of methoxy poly(ethylene glycol)/poly(epsilon-caprolactone) amphiphilic blockk copolymeric nanospheres for tumor-specific folate-mediated targeting of anticancer drugs. *Biomaterials* , 1053-1061.

Parveen, S., & Sahoo, S. (2008). Polymeric nanoparticles for cancer therapy. *J Drug Target* , 108-123.

Pastorino, F., Brignole, C., & Di Paolo, D. (2006). Targeting liposomal chemotherapy via both tumor cell-specific and tumor, vasculature-specific ligands potentiates therapeutic efficacy. *Cancer Res.* , 10073-10082.

Patri, A., Kukowska-Latallo, J., & Baker, J. J. (2005). Targeted drug delivery with dendrimers: comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex. *Adv. Drug Deliv. Rev.* , 2203-2214.

Pelicano, H., Martin, D., Xu, R., & Huang, P. (2006). Glycolysis inhibition for anticancer treatment. *Oncogene* , 4633-4646.

Prabhu, R. H., Patravale, V. B., & Joshi, M. D. (2015). Polymeric nanoparticles for targeted treatment in oncology: current insights. *International Journal of Nanomedicine* , 1001-1018.

Pridgen, E., Alexis, F., & Farokhzad, O. (2014). Polymeric nanoparticle technologies for oral drug delivery. *Clin. Gastroenterol Hepatol* , 1605-1610.

Ran, S., Downes, A., & Thorpe, P. (2002). Increased exposure of anionic phospholipids on the surface of tumor blood vessels. *Cancer Res* , 6132-6140.

Rodrigues, J. e. (2003). Novel core (polyester)-shell (polysaccharide) nanoparticles: protein loading and surface modification with lectins. *J. Control Release* , 103-112.

Sahoo, S., & Labhasetwar, V. (2005). Enhanced antiproliferative activity of transferrin conjugated paclitaxel loaded nanoparticles is mediated via sustained intracellular drug retention. *Mol Pharm* , 373-383.

Shadidi, M., & Sioud, M. (2003). Selective targeting of cancer cells using synthetic peptides. *Drug Resist. Updat* , 363-371.

Shen, Z., Wei, W., Tanaka, H., Kohama, K., Ma, F., & Dobashi, T. e. (2011). A galactosamine-mediated drug delivery carrier for targeted liver cancer therapy. *Pharmacol. Res.* , 410.

Sheng, Y. e. (2009). In vitro macrophage uptake and in vivo biodistribution of PLA-PEG nanoparticles loaded with hemoglobin as blood substitutes: effect of PEG content. *Mater Sci Mater Med* , 1881-1889.

Shikata, F., Tokumitsu, H., Ichikawa, H., & Fukumori, Y. (1998). In vitro cellular accumulation of gadolinium incorporated into chitosan nanoparticles designed for neutron capture therapy of cancer. *Eur. J. Phar. Biopharm* , 57-63.

Shroff, K., & Vidyasagar, A. (2013). Polymer Nanoparticles: Newer Strategies towards Targeted Cancer Therapy. *J. Phys Chem Biophys* .

Sinha, R., Kim, G., & Shin, D. (2008). Therapeutic nanoparticles for drug delivery in cancer. *Clin. Cancer. Res* , 1310-1316.

Sudimack, J., & Lee, R. (2000). Targeed drug delivery via the folate receptor. *Adv. Drug Deliv. Rev.* , 147-162.

Sutton , D., Nasongka, N., Blanco, E., & Gao, J. (2007). Functionalized micellar systems for cancer targeted drug delivery. *Pharm Res.* , 1029-1046.

Sutton, D., Nasongkla, N., Blanco, E., & Gao, J. (2007). Functionalized micellar systems for cancer targeted drug delivery. *Pharm. Res.* , 2569-2589.

Svenson, S., & Tomalia, D. (2005). Dendrimers in biomedical applications-refelections on the field. *Adv. Drug Delivery* , 2106-2129.

Thompson, D. (1997). Cyclodextrins as enabling excipients: their present and future use in pharmaceuticals. *CRC Crit. Rev. Ther. Drug Carr. Syst.* , 1-110.

Tokumitsu, H., Hiratsuka, J., Sakurai, Y., Kobayashi, T., Ichikawa, H., & Fukumori, Y. (2000). Gadolinium neutro-capture therapy using novel gadopentetic acid-chitsan complex nanoparticles: in vivo growth suppression of experimental melanoma solid tumor. *Cancer Lett.* , 177-182.

Torchilin, V., Lukyanov, A., Gao, Z., & Papahadjopoulos-Sternberg, B. (2003). Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs. *Proc. Natl. Acad. Sci. USA* , 6039-6044.

Tuerk, C., & Gold, L. (1990). Systematic evolution of ligands by exponential enrichment:RNA ligands to bacteriophage T4 DNA polymerase. *Science* , 505-510.

Uhrich, K., Cannizzaro, S., Langer, R., & Shakesheff, K. (1999). Polymeric systems for controlled drug release. *Chem. Rev* , 3181-3198.

Upadhyay, K., Mishra, A., & Chuttani, K. e. (2012). The in vivo behavior and antitumor activity of doxorubicin-loaded poly(γ-benzyl l-glutamate)- block-hyaluronan polymersomes in Ehrlich ascites tumor-bearing BalB/c mice. . *Nanomedicine* , 71-80.

Van Cutsem, E., Kohne, C., Hitre, E., Zaluski, J., Chang Chien, C., & Makhson, A. (2009). Cetuximab and chemotherapy as initial treatmnt for metastatic colorectal cancer. *N. Engl J Med* , 17.

van Steenis, J., van Maarseveen, E., & Verbaan, F. (2003). Preparation and characterization of folate-targeted PEG-coated pDMAEMA-based polyplexes. *J. Control Release* , 167-176.

Vega, J., Ke, S., Fan, Z., Wallace, S., Charsangavej, C., & Li, C. (2003). Targeting doxorubicin to epidermal growth factor receptors by site specific conjugation of C225 to poly(l-glutamic acid) through a polyethylene glycol spacer. *Pharm. Res.* , 826-832.

Vihinen, P., Ala-aho, R., & Kahari, V. (2005). Matrix metalloproteinases as the therapeutic targets in canceer. *Curr. Cancer Drug Targets* , 203-220.

Vlerken, L., & Amiji, M. (2006). Multi-functional polymeric nanoparticles for tumour-targeted drug delivery. *Expert Opinion Drug Delivery* , 205-216.

Vlerken, L., & Amiji, M. (2006). Multi-functional polymeric nanoparticlesfor tumour-targeted drug delivery. *Expert Opinion Drug Delivery* , 205-216.

Voura, E., Jaiswal, J., Matoussi, H., & Simon, S. (2004). Tracking metastatic tumor cell extravasation with quantum dot nanocrystals and fluorescence emission-scanning microscopy. *Nat. Med.* , 993-998.

Wang, A., Gu, F., Zhang, L., Chan, J., Radovich-Moreno, A., & Shaikh, M. e. (2008). Biofunctionalized targeted nanoparticles for therapeutic application. *Expert Opin. Biol. Ther.* , 1063-1070.

Wang, F., Bronich, T., Kabanov, A., Rauh, R., & Roovers, J. (2005). Synthesis and evaluation of a star amphiphilic block copolymer from poly(epsilon-caprolactone) and poly(ethyelene glycol) as a potential drug delivery carrier. *Bioconjug. Chem.* , 397-405.

Wang, J., Tang, G., & Shen, J. e. (2012). A gene nanocomplex conjugated with monoclonal antibodies for targeted therapy of hepatocellular carcinoma. *Biomaterials* , 4597-4607.

Wang, Y., Yu, L., Han, L., Sha, X., & Fang, X. (2007). Difunctional pluronic copolymer micelles for paclitaxel delivery: synergistic effect of folate-mediated targeting and pluronic-mediated overcoming multidrug resistance in tumor cell lines. *Int. J. Pharm.* , 63-73.

Wong, H., Bendayan, R., Rauth, A., Babakhanian, K., & Wu, X. (2006). A mechanistic study of enhance doxorubin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system. *J Pharmacol Exp Ther.* , 1372-1381.

Wong, H., Rauth, A., & Bendayan, R. e. (2006). A new polymer-lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug resistanc human breast cancer cells. *Pharm. Res.* , 1574-1585.

Wouessidjewe, D., Skiba, M., Leroy-Lechat, F., & Duchene, D. (1996). A new concept in drug delivery based on 'skirt-shaped cyclodextrins aggregates' present state and future prospects. *STP Pharma Sci.* , 21-26.

Xu, J., Zhao, Q., Jin, Y., & Qiu, L. (2014). High loading of hydrophilic/hydrophobic doxorubicin into polyphosphazene polymersome for breast cancer therapy. *Nanomedicine* , 349-358.

Xu, L., Pirollo, K., Tang, W., Rait, A., & Chang, E. (1999). Transferrin liposome mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts. *Hum Gene Ther* , 2941-2952.

Yang, Y., Zhang, Z., Chen, L., Gu, W., & Li, Y. (2010). Galactosylated poly(2-(2-aminoethyoxy)ethoxy)phosphazene/DNA complex nanoparticles: in vitro and in vivo evaluation for gene delivery. *Biomacromolecules* , 927-933.

Yatvin, M., Kreutz, W., Horwitz, B., & Shinitzky, M. (1980). pH-sensitive liposomes: possible clinical implications. *Science* , 1253-1255.

Yoo, H., & Park, T. (2004). Folate receptor targeted biodegradable polymeric doxorubicin micelles. *J. Control Release* , 273-283.

Yu, M. K., Park, J., & Jon, S. (2012). Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. *Theranostics* , 3-17.

Zhang, H., Ma, Y., & Sun, X. (2010). Recent developments in carbohydrate decorated targeted drug/gene delivery. *Med. Res. Rev* , 270-289.

Zhang, L., Chan, J., & Gu, F. e. (2008). Self-assembled lipid-polymer hybrid nanoparticles: a robust drug delivery platform. *ACS Nano.* , 1696-1702.

Zhao, G., Tanaka, H., & Kim, C. e. (2014). Histidinylated poly-l-lysine-based vectors for cancer-specific gene expression via enhancing the endosomal escape. *J. Biomater. Sci. Polym. Ed.* , 519-534.